Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.
Diagnosis & Disease Information
Can Treatments for Childhood ALL Alter the Gut Microbiome?
New research confirms that gut microbiome dysbiosis is present in survivors of childhood acute lymphoblastic leukemia.
EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML
EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.
Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
Although results indicated rivaroxaban decreased the risk of VTE and VTE-related death in patients with cancer, the benefit was not maintained at study conclusion.
Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.
CAR-T Cells Successfully Manufactured at Point-of-Care
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.
- Loading...
Loading...
Next post in ASH 2018
Loading... 
Loading...